Literature DB >> 16231014

Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners.

C G Roehrborn1, L Marks, R Harkaway.   

Abstract

This questionnaire-based survey evaluated the frequency and severity of lower urinary tract symptoms (LUTS) and the prevalence of enlarged prostate (EP) diagnosis and its impact on quality of life and spousal relationships among >1000 American men aged >50 years. A quarter of men suffered moderate to severe LUTS and 55% of those consulting a doctor had EP. EP negatively affected patient quality of life and caused relationship strain with spouses. These findings confirm that LUTS and EP are prevalent in the US population, affecting both patient and spouse, and may help in developing management strategies for EP.

Entities:  

Mesh:

Year:  2006        PMID: 16231014     DOI: 10.1038/sj.pcan.4500841

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  12 in total

1.  Ahead of the curve.

Authors:  David B Nash
Journal:  Popul Health Manag       Date:  2013       Impact factor: 2.459

2.  Effect of an employer-sponsored health and wellness program on medical cost and utilization.

Authors:  Hangsheng Liu; Katherine M Harris; Sarah Weinberger; Seth Serxner; Soeren Mattke; Ellen Exum
Journal:  Popul Health Manag       Date:  2012-07-23       Impact factor: 2.459

3.  Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues.

Authors:  Tyler M Bauman; Priyanka D Sehgal; Karen A Johnson; Thomas Pier; Reginald C Bruskewitz; William A Ricke; Wei Huang
Journal:  Prostate       Date:  2014-04-30       Impact factor: 4.104

4.  Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Samuel R Denmeade; Blair Egerdie; Gary Steinhoff; Rosemina Merchant; Ralph Abi-Habib; Peter Pommerville
Journal:  Eur Urol       Date:  2010-11-24       Impact factor: 20.096

5.  Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia.

Authors:  Mostafa M Elhilali; Peter Pommerville; Richard C Yocum; Rosemina Merchant; Claus G Roehrborn; Samuel R Denmeade
Journal:  J Urol       Date:  2012-11-07       Impact factor: 7.450

6.  Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-08-01

7.  Partners agree that the treatment of LUTS reduces patients' bother and improves their quality of life: prospective 12 years follow-up study.

Authors:  Said Fadel Mishriki; Samuel J S Grimsley; Ghulam Nabi; Nicholas Paul Cohen
Journal:  World J Urol       Date:  2009-07-24       Impact factor: 4.226

Review 8.  Cellular senescence as a possible link between prostate diseases of the ageing male.

Authors:  Gaelle Fiard; Vasilis Stavrinides; Emma S Chambers; Susan Heavey; Alex Freeman; Rhys Ball; Arne N Akbar; Mark Emberton
Journal:  Nat Rev Urol       Date:  2021-07-22       Impact factor: 14.432

9.  The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases.

Authors:  Faris Azzouni; Alejandro Godoy; Yun Li; James Mohler
Journal:  Adv Urol       Date:  2011-12-25

10.  Men's lower urinary tract symptoms are also mental and physical sufferings for their spouses.

Authors:  Sae Chul Kim; Shin Young Lee
Journal:  J Korean Med Sci       Date:  2009-04-20       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.